Loading
The first ADC to extend life in cervical cancer, for women whose disease has come back after chemotherapy.
innovaTV 301, also ENGOT-cx12 and GOG-3057, trial NCT04697628 sponsored by Genmab and Pfizer through Seagen and published in the New England Journal of Medicine in 2024, produced the first antibody-drug conjugate to extend life in cervical cancer, for women whose disease has returned after one or two lines including platinum. It randomised 502 patients to tisotumab vedotin or investigator's choice chemotherapy, met its primary overall survival endpoint, improved progression-free survival and tripled the response rate, leading to full FDA approval in April 2024; ocular events in about half, mostly conjunctivitis, plus neuropathy and bleeding require mitigation. OnCo links it to cervical cancer, antibody-drug conjugates, tissue factor as a target, tisotumab vedotin, Ignace Vergote and Bradley J. Monk. Whether the drug can move earlier or combine with immunotherapy is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
502 enrolled.
Shares Tissue factor, Tisotumab vedotin, Recurrent or metastatic cervical cancer, Cervical cancer.
Shares Tisotumab vedotin, Recurrent or metastatic cervical cancer, Cervical cancer, Antibody-drug conjugate (ADC).
Shares Tisotumab vedotin, Genmab, Antibody-drug conjugate (ADC).
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Antibody-drug conjugate (ADC).
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Antibody-drug conjugate (ADC).
Shares Recurrent or metastatic cervical cancer, Cervical cancer, Antibody-drug conjugate (ADC).
Shares Bradley J. Monk, Cervical cancer.
Shares Bradley J. Monk, Recurrent or metastatic cervical cancer, Cervical cancer.